基因编辑技术 - 公司正在部署Prime Editing技术，这是一种多样化、精准和高效的基因编辑技术[104][105] - 公司相信Prime Editing项目有望利用迄今为止在基因疗法、基因编辑和递送途径方面取得的临床、监管和制造进展，加快进入临床试验和潜在批准[107] 血液项目 - 慢性肉芽肿病是公司最先进的血液项目，正在推进PM359作为治疗该疾病的候选药物[106] 研发费用 - 研发费用将继续大幅增加,主要用于开发任何未来的候选药物,包括制造方面的投资[113] - 一般及行政费用也将增加,以支持日益增长的研发活动[115] 财务状况 - 截至2024年6月30日,公司拥有1.629亿美元的现金、现金等价物和投资,不包括受限现金,或1.764亿美元,包括受限现金[134] - 公司截至2024年6月30日的财务报表是基于持续经营假设编制的，但公司能否持续经营存在不确定性[138] - 2024年上半年经营活动现金流出1.132亿美元，主要包括1.011亿美元净亏损、135万美元应付关联方结算款变动、92万美元应付账款变动等[140,141] - 2024年上半年投资活动现金流出3,013.8万美元，主要包括2,590万美元购买净额增加和420万美元购买固定资产[142] - 2024年上半年筹资活动现金流入1.574亿美元，主要包括1.321亿美元公开发行普通股、1,880万美元发行预付款认股权证以及600万美元收到囊性纤维化基金款项[143] - 公司预计现有现金、现金等价物和投资将可为运营和资本支出提供资金支持至2025年第二季度[145,146] - 公司未来可能需要通过多种方式筹集额外资金以支持研发、临床试验、知识产权保护等[146,147,148] - 公司2024年上半年无重大合同义务和承诺变化[149,150]

临床试验进展 - 公司在第二季度获得FDA批准,将PM359进入临床试验,计划于2025年公布初步临床数据[2] - 公司正在推进多个核心领域的项目,包括血液和免疫、肝脏、眼科和神经肌肉等,并计划在2024年内取得多项里程碑进展[3,6,7] 财务情况 - 第二季度研发费用为4310万美元,较上年同期增加24.5%,主要由于公司管线和平台的推进[9] - 第二季度净亏损为5530万美元,较上年同期增加30.5%[11] - 截至2024年6月30日,公司现金、现金等价物和投资总额为1.764亿美元,较2023年12月31日增加30.3%[12] 技术平台 - 公司相信Prime Editing技术可以修复几乎所有类型的遗传突变,并在多种组织和细胞类型中发挥作用,有望在数千种适应症中发挥潜力[13,14] - 公司相信Prime Editing技术的模块化特性将有助于加速和降低风险,更有效地执行临床开发计划[17] 管理团队 - 公司宣布Mohammed Asmal博士晋升为首席医疗官,加强管理团队[4] 未来规划 - 公司正在探索业务发展机会,以加快现有工作并扩大Prime Editing技术的影响范围[17] - 公司预计将在2024年建立AAV递送平台和给药途径,支持神经肌肉项目的进展[8]

Prime Medicines (PRME) has made encouraging pipeline progress of late and investors will focus on related updates when it reports second-quarter 2024 results next month. Surprise - Reported Earnings Histor The Zacks Consensus Estimate for loss per share in the second quarter is pinned at 40 cents. | --- | --- | --- | --- | --- | |----------------------|----------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | Magnitude Consensus Estimate Trend (60 Days) | | | | | | ...

Prime Medicine, Inc.’s (PRME) shares have risen 16.4% in the past three months compared with the industry’s growth of 10.9%. The stock has also outperformed the sector and the S&P 500.The encouraging pipeline progress of this biotechnology company, focused on developing the next generation of gene editing therapies, is a positive. Innovation is imperative in the dynamic biotech sector and companies with a differentiated pipeline catch the eye of investors.PRME Outperforms Industry, Sector & S&P 500Image Sou ...

Shares of Prime Medicine, Inc. (PRME) have gained 24.1% over the past four weeks to close the last trading session at $6.54, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.45 indicates a potential upside of 121%. The average comprises 11 short-term price targets ranging from a low of $9 to a high of $21, with a standard deviation of $4.34. While the lowest estimate indicate ...

Shares of Prime Medicine, Inc. (PRME) have gained 18% over the past four weeks to close the last trading session at $6.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15 indicates a potential upside of 133.6%.The average comprises 10 short-term price targets ranging from a low of $9 to a high of $21, with a standard deviation of $4.32. While the lowest estimate indicates an ...

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY. A live audio webcast of the fireside chat will be availabl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission file number 001-41536 Prime Medicine, Inc. (Exact name of registrant as specified in its charter) Delawa ...

Exhibit 99.1 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates -- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 -- -- Appointed Tony Coles, M.D. as senior advisor -- Cambridg ...

-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 -- -- Appointed Tony Coles, M.D. as senior advisor -- CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company ...